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Summary  
Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders in which 
~1 in 20 affected individuals show autosomal dominant inheritance. In such cases, there may be gain-
of-function mutations in CARD14, encoding caspase recruitment domain-containing protein 14 
(CARD14) that activates the non-canonical nuclear factor-kappa B (NF-κB) pathway, thereby 
promoting cutaneous inflammation. Here, we report a mother and son with PRP due to a new 
missense mutation in CARD14 and describe the beneficial clinical effects of ustekinumab, a 
monoclonal antibody against interleukins-12 and -23, in both subjects. A 49 year-old female and her 
20 year-old son had lifelong, generalised, patchy erythematous scale with a few islands of sparing, as 
well as minor nail ridging and mild palmoplantar keratoderma, features consistent with generalised 
PRP. Topical steroids, phototherapy and oral retinoids proved ineffective therapies. Following 
informed consent, Sanger sequencing of CARD14 in both individuals revealed a new heterozygous 
single nucleotide transversion in exon 16, c.356T>G, resulting in the missense mutation, 
p.Met119Arg. Ustekinumab, at a dose of 45mg every 12 weeks, brought about a significant physical 
and emotional improvement in both the mother and son within a few days of the initial dose, which 
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was sustained on maintenance dosing. This report highlights the therapeutic potential of biologics that 
downregulate NF-kB signalling in familial PRP with mutations in CARD14.  
 
What’s already known about this topic? 
• Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders in 
which some cases show autosomal dominant inheritance; some cases also reveal heterozygous 
gain-of-function mutations in CARD14, encoding caspase recruitment domain-containing protein 
14 (CARD14). 
• Ustekinumab, an IL12/23 antagonist, is a licensed biological therapy for psoriasis, although its 
use has not been widely assessed in PRP, despite anecdotal reports of its potential efficacy. 
 
What does this study add? 
• We report a mother and son with refractory generalised PRP. DNA sequencing revealed they both 
carried a new de novo missense mutation in CARD14, p.Met119Arg. 
• Identification of this CARD14 mutation was used as justification for a trial of ustekinemab, 
whereupon both subjects had a beneficial clinical response, physically and emotionally, with 
sustained improvements over several months of follow up. 
• Ustekinumab may be considered as a targeted anti-inflammatory therapy for familial PRP with an 
underlying mutation in CARD14.  
 
Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders, 
which may show clinico-pathological overlap with psoriasis.1,2 Most cases of PRP are sporadic but ~1 
in 20 show autosomal dominant inheritance.3 Moreover, some familial PRP has been shown to result 
from gain-of-function mutations in CARD14, encoding caspase recruitment domain-containing 
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protein 14 (CARD14).1 CARD14, also known as CARD-containing membrane-associated guanylate 
kinase (MAGUK) protein 2 (Carma 2), is a member of a family of scaffold proteins involved in cell 
adhesion, signal transduction and cell polarity control.4 CARD14 binds to B cell lymphoma 10 
(BCL10) through a CARD-CARD interaction and activates the non-canonical nuclear factor-kappa B 
(NF-κB) pathway, thus promoting inflammation.4 
 The significance of CARD14 mutations in PRP may also extend to therapy since a few 
previous reports have highlighted good clinical responses to biologics, such as ustekinumab, when 
conventional anti-inflammatory therapies have not led to patient benefit.5-8 Of all the reports, 
however, the benefit of ustekinumab was demonstrated in only one case with a known CARD14 
mutation.8 In this report, we describe a mother and son with generalised PRP, identify a new CARD14 
mutation, and demonstrate major physical and emotional improvements following treatment with 
ustekinumab. 
 
Case Report 
A 49 year-old female presented with widespread erythema and scale. Her skin had been 
normal at birth but around aged six weeks she developed erythematous patches on both cheeks 
followed by more generalised dry red scales with peeling that persisted into adulthood. Examination 
revealed generalised, confluent erythematous scale affecting the face, body and limbs, and a few 
islands of spared, apparently unaffected skin. She had minor nail ridging and mild palmoplantar 
keratoderma. Her 20 year-old son had a similar clinical course that began in his first few weeks of life 
although his skin developed more patchy, serpiginous, dry and thick scale with associated erythema. 
A clinical diagnosis of autosomal dominant familial PRP was made (pedigree is shown in Fig. 1a). 
Treatment with oral retinoids, phototherapy, and topical steroids proved ineffective in both subjects.  
Following informed consent, Sanger sequencing of CARD14 using peripheral blood DNA as 
template, was performed on both affected and all unaffected members of the family. This revealed a 
heterozygous single nucleotide transversion c.356T>G in exon 16, which converts methionine (ATG) 
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to arginine (AGG), designated p.Met119Arg (Fig 1b). This missense mutation was detected in both 
the affected mother and her son but not in other unaffected relatives nor in >120,000 control alleles 
(http://exac.broadinstitute.org/gene/ENSG00000141527). This amino acid substitution is located 
adjacent to other gain-of-function mutations between the CARD and coiled-coil domain.1,9 The 
functional effect of this missense mutation, assessed with various programs,10-14 strongly indicates its 
pathogenic potential that p.Met119Arg is a pathologic variant (SIFT: 0.107, tolerated; PolyPhen-2: 
0.244, benign; MutationTaster: 0.999, disease causing; CADD: 23.9, damaging; DANN: 0.964, 
pathogenic).  
Both mother (weight=66kg) and son (weight=65kg) were treated with sub-cutaneous 
ustekinumab 45mg every 12 weeks after two loading doses at weeks 0 and 4. Both Psoriasis Area 
Severity Index (PASI) – adopted as a measure of disease severity for PRP, and Dermatology Quality 
of Life Index (DLQI) were assessed for the mother and son at baseline, 12 weeks and 24 weeks after 
the initiation of ustekinumab. At baseline, the mother had a PASI of 25.7 and DLQI 18, and the son 
had a PASI of 29.2 and DLQI 22. A dramatic clinical improvement was observed within a few days 
of the initial loading dose and was clearly evident after 12 weeks with corresponding PASI<1 and 
DLQI 0 for the mother, and PASI 4.8 and DLQI 3 for the son (Fig. 1c), which persisted for a total of 
24 weeks. The clinical benefit in the mother, however, waned around 30 weeks after initiation, but the 
skin improved again after the dose of ustekinumab was increased from 45mg to 90mg 12-weekly. 
Approximately 12 weeks after the ustekinumab dose increase, the mother had normal fingernails for 
the first time in her life. Both individuals have been observed for >8 months on treatment and the 
improvement has been maintained. For individuals with psoriasis, an HLA-Cw6 genotype has been 
associated with an improved response to ustekinumab but genotyping in both mother and son with 
PRP (using published methods, ref. 15) revealed that they were both HLA-Cw6-negative. There were 
noticeable personal benefits for both individuals, due to improved physical and emotional wellbeing, 
following the improvement with ustekinumab after many years of impaired quality of life due to PRP. 
Details of the positive impact the ustekinumab had on the mother’s life are recorded in her own words 
in the Supplementary material. 
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In summary, the positive response to treatment with ustekinumab in both the mother and son 
highlights the efficacy of this biologic therapy in PRP, with the discovery of an underlying mutation 
in CARD14 being the driver towards pursuing this particular targeted anti-inflammatory therapy.  
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Figure Legends 
 
Fig. 1. Pedigree, molecular pathology and clinical features of the mother and son with 
autosomal dominant pityriasis rubra pilaris. 
(a) Pedigree: Sanger sequencing of CARD14 was performed in all family members (affected and 
unaffected) shown in this autosomal dominant pedigree (mother is indicated by arrow); (b) 
Heterozygous missense mutation (c.356T>G; p.Met119Arg) in CARD14, which was present in the 
affected mother and son but none of the other unaffected family members; (c) Clinical responses at 
baseline and after 12 weeks therapy with ustekinumab in the mother and son. 
 
Supplementary Material 
 
A personal account by the mother with familial PRP on “how ustekinumab has changed (her) life”.  
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